ABUS Effective Screening Alternative to MRI
Automated breast ultrasound (ABUS) is as effective as MRI in breast cancer screening in women with dense breast tissue, researchers say.
Automated breast ultrasound (ABUS) is as effective as MRI in breast cancer screening in women with dense breast tissue, show results of a study published in the July/August issue of Journal of Diagnostic Medical Sonography. In addition, the ABU’s short examination time and ease of use may make it a practical choice in many situations.
For this preliminary study, researchers from Nova Southeastern University in Winter Springs, Fla., assessed 24 asymptomatic women with more than 50 percent breast density on digital mammography. Each woman underwent an ABUS exam, which was followed a week later by a 3D contrast breast MRI. After comparing the two examinations, the researchers found 15 malignant tumors and nine benign pathologies.
Comparable diagnostic reliability was observed between the ABUS and the MRI in differentiating benign from malignant breast lesions based on similar morphologic criteria.
ABUS is cleared for diagnostic use, but not specifically for screening in women with dense breasts. ABUS does have disadvantages, including the inability to compress the breast tissue and the ability to view tissue or lesion vascularity. However, advantages to the procedure include that it is not invasive and that it is simple to use with less technical training than an MRI requires, perhaps making it more viable to screen larger groups of people.
The authors concluded that ABUS is a promising cost-effective adjunct diagnostic modality to MRI in the evaluation women with increased breast density by digital mammography.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
